KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis

Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angio-genesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new ben-...

Full description

Saved in:
Bibliographic Details
Published in:Experimental & molecular medicine 2006, 38(5), , pp.502-508
Main Authors: 이의연, 박시영, 송현석, 손명진, 이규양, 유성은, 김영진
Format: Article
Language:Korean
Subjects:
생화학
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angio-genesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new ben-zopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogene-sis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers. KCI Citation Count: 13
ISSN:1226-3613
2092-6413